Adverse events following first and second dose COVID-19 vaccination in England, October 2020 to September 2021: a national vaccine surveillance platform self-controlled case series study
dc.contributor.author | Tsang, RSM | |
dc.contributor.author | Joy, M | |
dc.contributor.author | Byford, R | |
dc.contributor.author | Robertson, C | |
dc.contributor.author | Anand, SN | |
dc.contributor.author | Hinton, W | |
dc.contributor.author | Mayor, N | |
dc.contributor.author | Kar, D | |
dc.contributor.author | Williams, J | |
dc.contributor.author | Victor, W | |
dc.contributor.author | Akbari, A | |
dc.contributor.author | Bradley, DT | |
dc.contributor.author | Murphy, S | |
dc.contributor.author | O’Reilly, D | |
dc.contributor.author | Owen, RK | |
dc.contributor.author | Chuter, A | |
dc.contributor.author | Beggs, J | |
dc.contributor.author | Howsam, G | |
dc.contributor.author | Sheikh, A | |
dc.contributor.author | Hobbs, FDR | |
dc.contributor.author | de Lusignan, S | |
dc.date.accessioned | 2024-03-07T15:28:51Z | |
dc.date.available | 2024-03-07T15:28:51Z | |
dc.date.issued | 2023-01-19 | |
dc.identifier.issn | 1560-7917 | |
dc.identifier.issn | 1560-7917 | |
dc.identifier.uri | https://pearl.plymouth.ac.uk/handle/10026.1/22137 | |
dc.description.abstract |
<jats:sec> <jats:title>Background</jats:title> <jats:p>Post-authorisation vaccine safety surveillance is well established for reporting common adverse events of interest (AEIs) following influenza vaccines, but not for COVID-19 vaccines.</jats:p> </jats:sec> <jats:sec> <jats:title>Aim</jats:title> <jats:p>To estimate the incidence of AEIs presenting to primary care following COVID-19 vaccination in England, and report safety profile differences between vaccine brands.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>We used a self-controlled case series design to estimate relative incidence (RI) of AEIs reported to the national sentinel network, the Oxford-Royal College of General Practitioners Clinical Informatics Digital Hub. We compared AEIs (overall and by clinical category) 7 days pre- and post-vaccination to background levels between 1 October 2020 and 12 September 2021.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Within 7,952,861 records, 781,200 individuals (9.82%) presented to general practice with 1,482,273 AEIs, 4.85% within 7 days post-vaccination. Overall, medically attended AEIs decreased post-vaccination against background levels. There was a 3–7% decrease in incidence within 7 days after both doses of Comirnaty (RI: 0.93; 95% CI: 0.91–0.94 and RI: 0.96; 95% CI: 0.94–0.98, respectively) and Vaxzevria (RI: 0.97; 95% CI: 0.95–0.98). A 20% increase was observed after one dose of Spikevax (RI: 1.20; 95% CI: 1.00–1.44). Fewer AEIs were reported as age increased. Types of AEIs, e.g. increased neurological and psychiatric conditions, varied between brands following two doses of Comirnaty (RI: 1.41; 95% CI: 1.28–1.56) and Vaxzevria (RI: 1.07; 95% CI: 0.97–1.78).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>COVID-19 vaccines are associated with a small decrease in medically attended AEI incidence. Sentinel networks could routinely report common AEI rates, contributing to reporting vaccine safety.</jats:p> </jats:sec> | |
dc.format.extent | 20-32 | |
dc.format.medium | ||
dc.language | en | |
dc.publisher | European Centre for Disease Control and Prevention (ECDC) | |
dc.subject | COVID-19 | |
dc.subject | COVID-19 Vaccines | |
dc.subject | Drug-Related Side Effects and Adverse Reactions | |
dc.subject | Medical record systems, computerised | |
dc.subject | Primary care | |
dc.subject | SNOMED CT | |
dc.subject | Sentinel surveillance | |
dc.subject | Vaccination | |
dc.subject | Humans | |
dc.subject | BNT162 Vaccine | |
dc.subject | ChAdOx1 nCoV-19 | |
dc.subject | COVID-19 | |
dc.subject | COVID-19 Vaccines | |
dc.subject | England | |
dc.subject | Influenza Vaccines | |
dc.subject | Vaccination | |
dc.title | Adverse events following first and second dose COVID-19 vaccination in England, October 2020 to September 2021: a national vaccine surveillance platform self-controlled case series study | |
dc.type | journal-article | |
dc.type | Article | |
plymouth.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36695484 | |
plymouth.issue | 3 | |
plymouth.volume | 28 | |
plymouth.publisher-url | http://dx.doi.org/10.2807/1560-7917.es.2023.28.3.2200195 | |
plymouth.publication-status | Published | |
plymouth.journal | Eurosurveillance | |
dc.identifier.doi | 10.2807/1560-7917.es.2023.28.3.2200195 | |
plymouth.organisational-group | |Plymouth | |
plymouth.organisational-group | |Plymouth|Faculty of Health | |
plymouth.organisational-group | |Plymouth|Users by role | |
plymouth.organisational-group | |Plymouth|Users by role|Academics | |
plymouth.organisational-group | |Plymouth|Faculty of Health|Peninsula Medical School | |
dc.publisher.place | Sweden | |
dc.date.updated | 2024-03-07T15:28:50Z | |
dc.identifier.eissn | 1560-7917 | |
dc.rights.embargoperiod | forever | |
rioxxterms.versionofrecord | 10.2807/1560-7917.es.2023.28.3.2200195 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |